Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)

Market Cap	39.61B +574.6%
Revenue (ttm)	1.38B +40.6%
Net Income	173.20M +416.4%
EPS	0.43 +437.5%
Shares Out	n/a
PE Ratio	228.67
Forward PE	118.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,606,395
Average Volume	2,722,844
Open	108.08
Previous Close	107.35
Day's Range	99.00 - 108.08
52-Week Range	48.06 - 116.50
Beta	n/a
RSI	57.37
Earnings Date	Mar 26, 2026

About SHA:688796

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 1,306
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688796

Financial Performance

In 2025, SHA:688796's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.